IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB

In present work, we studied cytokine levels and performed analysis of some immunologic parameters in the patients with chronic lymphocytic leukemia (CLL) before and after treatment with monoclonal anti-CD52 antibody (alemtuzumab). In comparison with a control group, the CLL patients before alemtuzum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. N Khorobrykh, T. P. Zagoskina, V. I. Shardakov, E. L. Nazarova, A. V. Yovdiy
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	chronic lymphocytic leukemia cytokines lymphocyte subsets alemtuzumab cd52 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d104345a4c674536b7bed7af0f268234
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d104345a4c674536b7bed7af0f268234
record_format	dspace
spelling	oai:doaj.org-article:d104345a4c674536b7bed7af0f2682342021-11-18T08:03:41ZIMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB1563-06252313-741X10.15789/1563-0625-2010-4-5-447-452https://doaj.org/article/d104345a4c674536b7bed7af0f2682342014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/408https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XIn present work, we studied cytokine levels and performed analysis of some immunologic parameters in the patients with chronic lymphocytic leukemia (CLL) before and after treatment with monoclonal anti-CD52 antibody (alemtuzumab). In comparison with a control group, the CLL patients before alemtuzumab treatment showed a significant decrease in relative contents of CD3+ and CD4+ lymphocytes, CD4+/CD8+ T cells, diminished IFNγ and IL-4 levels, and a trend for TNFα increase. After ceasing the alemtuzumab treatment, the patients with CLL exhibited a significant decrease in absolute amounts of mature T-lymphocytes, CD4+, CD8+, CD20+ cells, as well as decreased relative contents of CD16+ lymphocytes. A sufficient post-treatment drop of serum IL-2 concentrations and a trend for serum TNFα and IFNγ decrease were also observed, as compared with pre-treatment values. The changes revealed may be connected with an additional immunosuppressive effect of alemtuzumab. The dynamics of cytokine levels and immunological parameters associated with alemtuzumab treatment is indicative for a weakening of cell-mediated immunity, thus resulting into a potential risk of infectious complications.M. N KhorobrykhT. P. ZagoskinaV. I. ShardakovE. L. NazarovaA. V. YovdiySPb RAACIarticlechronic lymphocytic leukemiacytokineslymphocyte subsetsalemtuzumabcd52Immunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 12, Iss 4-5, Pp 447-452 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	chronic lymphocytic leukemia cytokines lymphocyte subsets alemtuzumab cd52 Immunologic diseases. Allergy RC581-607
spellingShingle	chronic lymphocytic leukemia cytokines lymphocyte subsets alemtuzumab cd52 Immunologic diseases. Allergy RC581-607 M. N Khorobrykh T. P. Zagoskina V. I. Shardakov E. L. Nazarova A. V. Yovdiy IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
description	In present work, we studied cytokine levels and performed analysis of some immunologic parameters in the patients with chronic lymphocytic leukemia (CLL) before and after treatment with monoclonal anti-CD52 antibody (alemtuzumab). In comparison with a control group, the CLL patients before alemtuzumab treatment showed a significant decrease in relative contents of CD3+ and CD4+ lymphocytes, CD4+/CD8+ T cells, diminished IFNγ and IL-4 levels, and a trend for TNFα increase. After ceasing the alemtuzumab treatment, the patients with CLL exhibited a significant decrease in absolute amounts of mature T-lymphocytes, CD4+, CD8+, CD20+ cells, as well as decreased relative contents of CD16+ lymphocytes. A sufficient post-treatment drop of serum IL-2 concentrations and a trend for serum TNFα and IFNγ decrease were also observed, as compared with pre-treatment values. The changes revealed may be connected with an additional immunosuppressive effect of alemtuzumab. The dynamics of cytokine levels and immunological parameters associated with alemtuzumab treatment is indicative for a weakening of cell-mediated immunity, thus resulting into a potential risk of infectious complications.
format	article
author	M. N Khorobrykh T. P. Zagoskina V. I. Shardakov E. L. Nazarova A. V. Yovdiy
author_facet	M. N Khorobrykh T. P. Zagoskina V. I. Shardakov E. L. Nazarova A. V. Yovdiy
author_sort	M. N Khorobrykh
title	IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
title_short	IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
title_full	IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
title_fullStr	IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
title_full_unstemmed	IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
title_sort	immune and cytokine status in patients with chronic lymphocytic leukemia receiving alemtuzumab
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/d104345a4c674536b7bed7af0f268234
work_keys_str_mv	AT mnkhorobrykh immuneandcytokinestatusinpatientswithchroniclymphocyticleukemiareceivingalemtuzumab AT tpzagoskina immuneandcytokinestatusinpatientswithchroniclymphocyticleukemiareceivingalemtuzumab AT vishardakov immuneandcytokinestatusinpatientswithchroniclymphocyticleukemiareceivingalemtuzumab AT elnazarova immuneandcytokinestatusinpatientswithchroniclymphocyticleukemiareceivingalemtuzumab AT avyovdiy immuneandcytokinestatusinpatientswithchroniclymphocyticleukemiareceivingalemtuzumab
_version_	1718422510361378816

IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB

Ejemplares similares